Discover and read the best of Twitter Threads about #jcopo
Most recents (1)
#OncoAlert Useful report in #JCOPO @ASCO_pubs on CNS outcomes in patients with #METex14 NSCLC. 83 patients with baseline CNS imaging; incidence of CNS metastases was 17% and an additional 19% developed CNS metastases later (lifetime risk 36%). #LCSM
ascopubs.org/doi/abs/10.120…
ascopubs.org/doi/abs/10.120…
#OncoAlert In the 30 patients who developed CNS metastases, 83% parenchymal and 17% leptomeningeal. Probability of developing CNS metastases at 3y was 38%. Keep this in mind during surveillance! OS between those who did vs didn't have CNS mets at baseline was 26.7m vs 27.2m #LCSM 
#OncoAlert Within this 83 patient METex14 cohort, 54 received crizotinib (RR 31%, TTD 7.8m, OS 13.7m). 22% had CNS progression (10% had intracranial ONLY progression) with a time to CNS progression of 5.8m. I think there's value in periodic brain MRI for most driver+ NSCLC. #LCSM
